Significance of high HDL cholesterol levels in Japanese men with metabolic syndrome

Internal Medicine

Volumn 50, Issue 19, 2011, Pages 2113-2120

  Hiratsuka, Noboru ^a,b   Yamada, Chizumi ^a   Mitsuhashi, Toshitake ^a   Inabe, Fumiyo ^a   Araida, Nami ^a   Takahashi, Eiko ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinjuku Center Bldg Clinic ^*  (Japan)

Author keywords

Heavy drinking; High density lipoprotein cholesterol; Insulin resistance; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALCOHOL DRINKING; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; EXERCISE; HUMANS; INSULIN RESISTANCE; JAPAN; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 80053603940     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5492     Document Type: Article

References (41)

1. Teramoto T, Sasaki J, Ueshima H, et al. Metabolic syndrome. J Atheroscler Thromb 15: 1-15, 2008.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002.
4. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366: 1059-1062, 2005.
5. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752, 2005.
6. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645, 2009.
7. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714, 1977.
8. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 46: 649-654, 1980.
9. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838, 1986.
10. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15, 1989.
11. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301-1310, 2007.
12. Tarui S. The report of Ministry of Health, Labor and Welfare research working group on primary hyperlipidemia. 1987 (in Japanese).
13. Maruyama T, Sakai N, Ishigami M, et al. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis 166: 177-185, 2003.
14. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEJM 364: 127-135, 2011.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
16. Ministry of Health, Labour and Welfare. The 5th Basic Survey of Cardiovascular Diseases, 2001 (in Japanese, http://www.mhlw.go. jp/toukei/saikin/hw/kenkou/jyunkan/jyunkan00/gaiyo.html).
17. Valmadrid CT, Klein R, Moss SE, et al. Alcohol intake and the risk of coronary heart disease mortality in persons with olderonset diabetes mellitus. JAMA 282: 239-246, 1999.
18. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 329: 1829-1834, 1993.
19. Rimm EB, Moats C. Alcohol and coronary heart disease: drinking patterns and mediators of effect. Ann Epidemiol 17(suppl): S3-S7, 2007.
20. Diehl AK, Fuller JM, Mattock MB, et al. The relationship of high density lipoproteins to alcohol consumption, and other lifestyle factors, and coronary heart disease. Atherosclerosis 69: 145-153, 1988.
21. Sillanaukee P, Koivula T, Jokeia H, et al. Relationship of alcohol consumption to changes in HDL-subfractions. Eur J Clin Invest 23: 486-491, 1993.
22. Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17: 1098-1105, 1997.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
24. Khurana M, Sharma D, Khandelwal PD. Lipid profile in smokers and tobacco chewers. a comparative study. J Assoc Physicians India 48: 895-897, 2000.
25. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 8: 405-411, 2006.
26. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a metaanalysis. Prev Med 37: 283-290, 2003.
27. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347: 1483-1492, 2002.
28. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101: 1727-1732, 2006.
29. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 167: 999-1008, 2007.
30. Weisweiler P. Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 65: 969-973, 1987.
31. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56: 320-328, 1992.
32. Burke V, Beilin LJ, Cutt HE, et al. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. J Clin Epidemiol 60: 133-141, 2007.
33. Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134, 2005.
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775, 2006.
35. Alkerwi A, Boutsen M, Vaillant M, et al. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis 204: 624-635, 2009.
36. Kiyohara Y, Kato I, Iwamoto H, et al. The impact of alcohol and hypertension on stroke incidence in a general Japanese population. The Hisayama Study. Stroke 26: 368-372, 1995.
37. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38: 1112-1117, 2001.
38. Kato I, Kiyohara Y, Kubo M, et al. Insulin-mediated effects of alcohol intake on serum lipid levels in a general population: the Hisayama Study. J Clin Epidemiol 56: 196-204, 2003.
39. Clerc O, Nanchen D, Cornuz J, et al. Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. Diabet Med 27: 1241-1249, 2010.
40. Hannuksela M, Marcel YL, Kesäniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 33: 737-744, 1992.
41. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17: 1053-1059, 1997.